Safety of galcanezumab in patients with episodic migraine: A randomized placebo-controlled dose-ranging Phase 2b study

• Published in: Cephalalgia Vol. 38; no. 6; pp. 1015 - 1025
• Main Authors: Oakes, Tina Marie Myers, Skljarevski, Vladimir, Zhang, Qi, Kielbasa, William, Hodsdon, Michael E, Detke, Holland C, Camporeale, Angelo, Saper, Joel R
• Format: Journal Article
• Language: English
• Published: London, England SAGE Publications 01.05.2018
• Subjects: Adolescent; Adult; Aged; Antibodies, Monoclonal - therapeutic use; Calcitonin Gene-Related Peptide - antagonists & inhibitors; Double-Blind Method; Female; Humans; Male; Middle Aged; Migraine Disorders - drug therapy; Treatment Outcome; Young Adult; calcitonin gene-related peptide; LY2951742; Galcanezumab; episodic migraine; safety; phase 2b study

Background Safety findings from a Phase 2b study of galcanezumab, a humanized monoclonal antibody against calcitonin gene-related peptide, for prevention of migraine (NCT02163993) are reported here. Methods Patients aged 18–65 years with episodic migraine were evaluated in this multicenter, double-b...